Plandai Biotechnology Inc (OTCMKTS:PLPL) stated that for the first three quarters ended March 31, 2015, the revenues stood at $64,024 compared to $250,859 in the same period, a year ago. The sales included the revenue of timber from the tea estate businesses in South Africa. With the increased factory activity in 2015, the cost of sales in the first nine months of fiscal jumped to $583,506 from $483,675 in the same period, a year earlier. More recently, Plandai Biotechnology reported that USN is formulating new unique products utilizing Phytofare® catechin complex.

MABVAX THERAPEUTICS (OTCMKTS:MBVX) HuMab 5B1 Antibody To Be Covered At World Molecular Imaging Congress

MABVAX THERAPEUTICS (OTCMKTS:MBVX) reported that its lead antibody, named as HuMab 5B1, will be a matter of focus in five separate presentations at the World Molecular Imaging Congress being held from September 2, 2015 to September 5, 2015. The research team from the Department of Radiology at MSK will present data on the use of company’s lead candidate as a PET imaging agent as well as a radio immunotherapy agent for pancreatic cancer treatment.

Presenters at the event include Jacob Houghton, Ph.D. who will highlight data from two preclinical in vivo trials utilizing the “HuMab 5B1” as an ImmunoPET imaging agent in respect of circulating antigen. He will also present new pre-targeted ways for the immunoPET imaging of CA19.9 in different murine models. Dalya Abdel-Atti will be another presenter at event who will showcase data of utilizing antibody in ImmunoPET imaging with newly advanced murine organoid models. A third presenter, Mr. Jan-Philip Meyer, Ph.D., will showcase results of using antibody as a pre-targeting agent.

Immunomedics, Inc. (NASDAQ:IMMU) To Participate At Upcoming Investor Conferences

Immunomedics, Inc. (NASDAQ:IMMU) reported that the company experts will participate in a Hematology and Oncology Panel at upcoming Wells Fargo Securities Healthcare Conference to be held on September 9, 2015.